Furthermore, in November 2024 another risk score was proposed for patients with HCC treated with combined hepatic arterial infusion chemotherapy (HAIC) and anti-PD-L1 immunotherapy, the AFCRPLITY score, which used aFP, CRP and PLR for the stratification of patients into risk groups (62). Here, CRP is linked to hepatocellular carcinoma.